The Leukemia & Lymphoma Society Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

The Leukemia & Lymphoma Society Inc (LLS) is a health organization that offers funding research, finding cures and access to treatments for blood cancer patients. The organizations services include patient support, health education, policy advocacy, funds raising and medical research funding. It offers treatments for various diseases, which include leukemia, lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms and myeloma. LLS offer diagnosis and treatement of blood cancers by funding academic research, therapy acceleration program and other specialized initiatives. The organization partners with pharmaceutical and biotechnology companies, patients support services and advocates working for blood cancer patients. It has operations in the US and Canada. LLS is headquartered in Rye Brook, New York, the US.

The Leukemia & Lymphoma Society Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
OncoPep Raises USD7 Million in Series B Venture Financing 11
Partnerships 12
NexImmune and Leukemia & Lymphoma Society Enter into Partnership 12
Selvita Enters into Agreement with Leukemia & Lymphoma Society 13
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 14
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 15
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 16
Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 17
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 18
Curis Enters Into Co-Development Agreement With The Leukemia & Lymphoma Society 19
Leukemia & Lymphoma Society Enters Into An Agreement With EpiZyme 21
Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 22
Equity Offering 23
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 23
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 24
The Leukemia & Lymphoma Society Inc - Key Competitors 25
The Leukemia & Lymphoma Society Inc - Key Employees 26
The Leukemia & Lymphoma Society Inc - Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Corporate Communications 29
Mar 16, 2017: LLS APPOINTS DR. GWEN NICHOLS, CHIEF MEDICAL OFFICER 29
Government and Public Interest 30
Nov 21, 2017: The Leukemia & Lymphoma Society awards grant to Savoldo for immunotherapy research 30
Nov 16, 2016: World Leading Cancer Organization Invests $40.3 Million in New Research to Find Cures 31
Product News 32
Oct 18, 2016: The Leukemia & Lymphoma Society Launches Groundbreaking Precision Medicine Approach to Treat Acute Myeloid Leukemia, One of the Deadliest Blood Cancers 32
Other Significant Developments 34
Nov 20, 2017: LLS Funds $46 Million in New Research to Find Cures 34
Nov 16, 2016: LLS Invests $40.3 Million in New Research to Find Cures 37
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List Of Tables

List of Tables
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Key Facts 2
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
The Leukemia & Lymphoma Society Inc, Deals By Therapy Area, 2011 to YTD 2017 8
The Leukemia & Lymphoma Society Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
OncoPep Raises USD7 Million in Series B Venture Financing 11
NexImmune and Leukemia & Lymphoma Society Enter into Partnership 12
Selvita Enters into Agreement with Leukemia & Lymphoma Society 13
Kite Pharma Enters into Agreement with Leukemia & Lymphoma Society 14
Evotec Enters Into Research Agreement With Leukemia & Lymphoma Society 15
Stemline Therapeutics Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 16
Constellation Pharma Enters Into Agreement With Leukemia & Lymphoma Society To Develop BET Inhibitors Drugs For Hematologic Cancers 17
The Leukemia & Lymphoma Society Enters Into Co-Development Agreement With Celator Pharma For CPX-351 18
Curis Enters Into Co-Development Agreement With The Leukemia & Lymphoma Society 19
Leukemia & Lymphoma Society Enters Into An Agreement With EpiZyme 21
Acetylon Pharma Enters Into Co-Development Agreement With Leukemia & Lymphoma Society 22
Kiadis Pharma Raises USD0.8 Million in Second Tranche of Private Placement of Shares 23
Kiadis Pharma Raises USD1 Million in Private Placement of Shares 24
The Leukemia & Lymphoma Society Inc, Key Competitors 25
The Leukemia & Lymphoma Society Inc, Key Employees 26

Toll Brothers Full Year Operating Financial

Toll Brothers 2023 Full Year Operating and Financial Review--SWOT Analysis, Technological Know-How, M&A, Senior Management, Goals and Strategies in the Global Real Estate Industry This report is part of the

USD 750 View Report

Myasthenia Gravis (MG) Market in China 2023

Myasthenia gravis (MG) is a rare autoimmune disorder that affects the muscles responsible for movement and breathing. It is caused by antibodies that attack the receptors on the muscles, preventing

USD 675 View Report

Leukemia & Lymphoma Society Inc - Strategic SWOT Analysis Review

Leukemia & Lymphoma Society Inc - Strategic SWOT Analysis Review market research report available in single user pdf license with Aarkstore Enterprise at USD 125

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available